IFN-γ-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy

Journal of Immunology

Volumn 166, Issue 11, 2001, Pages 6944-6951

  Pertl, Ursula ^a   Luster, Andrew D ^b   Varki, Nissi M ^c   Homann, Dirk ^a   Gaedicke, Gerhard ^d   Reisfeld, Ralph A ^a   Lode, Holger N ^d  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CELLULAR IMMUNITY; CHEMOTAXIS; CONTROLLED STUDY; CYTOLYSIS; FEMALE; GENE EXPRESSION; GENE THERAPY; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; METASTASIS; MITOSIS INHIBITION; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0035336451     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.11.6944     Document Type: Article

References (41)

1. Lode, H. N., T. Dreier, R. Xiang, N. M. Varki, A. S. Kang, and R. A. Reisfeld. 1998. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc. Natl. Acad. Sci. USA 95:2475.
2. Trinchieri, G. 1998. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70:83.
3. Luster, A. D., and P. Leder. 1993. IP-10, a C-X-C chemokine, elicits a potent thymus-dependent antitumor response in vivo. J. Exp. Med. 178:1057.
4. Nastala, C. L., H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiher, and W. J. Storkus. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697.
5. Tannenbaum, C. S., N. Wicker, D. Armstrong, R. Tubbs, J. Finke, R. M. Bukowski, and T. A. Hamilton. 1996. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J. Immunol. 156:693.
6. Yu, W. G., M. Ogawa, J. Mu, K. Umehara, T. Tsujimura, H. Fujiwara, and T. Hamaoka. 1997. IL-12-induced tumor regression correlates with in situ activity of IFN-γ produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J. Leukocyte Biol. 62:450.
7. Tannenbaum, C. S., R. Tubbs, D. Armstrong, J. H. Finke, R. M. Bukowski, and T. A. Hamilton. 1998. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor. J. Immunol. 161:927.
8. Coughlin, C. M., K. E. Salhany, M. S. Gee, D. C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J. E. Kim, L. Liu, et al. 1998. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25.
9. v antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc. Natl. Acad. Sci. USA 96:1591.
10. Strieter, R. M., S. L. Kunkel, D. A. Arenberg, M. D. Burdick, and P. J. Polverini. 1995. Interferon γ-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem. Biophys. Res. Comm. 210: 51.
11. Kanegane, C., C. Sgadari, H. Kanegane, J. Teruya-Feldstein, L. Yao, G. Gupta, J. M. Farber, F. Liao, L. Liu, and G. Tosato. 1998. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J. Leukocyte Biol. 64:384.
12. Wigginton, J. M., D. B. Kuhns, T. C. Back, M. J. Brunda, R. H. Wiltrout, and G. W. Cox. 1996. Interleukin 12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res. 56:1131.
13. Cassatella, M. A., S. Gasperini, F. Calzetti, A. Bertagnin, A. D. Luster, and P. P. McDonald. 1997. Regulated production of the interferon-γ-inducible protein-10 (IP-10) chemokine by human neutrophils. Eur. J. Immunol. 27:111.
14. + T cells and granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 188:133.
15. Yao, L., C. Sgadari, K. Furuke, E. T. Bloom, F. Teruya, and G. Tosato. 1999. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12. Blood 93:1612.
16. Angiolillo, A. L., C. Sgadari, D. D. Taub, F. Liao, J. M. Farber, S. Maheshwari, H. K. Kleinman, G. H. Reaman, and G. Tosato. 1995. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182:155.
17. Angiolillo, A. L., C. Sgadari, and G. Tosato. 1996. A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12. Ann. NY Acad. Sci. 795:158.
18. Taub, D. D., D. L. Longo, and W. J. Murphy. 1996. Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues and human peripheral blood lymphocytes-SCID mice. Blood 87:1423.
19. Farber, J. M. 1997. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukocyte Biol. 61:246.
20. Loetscher, M., B. Gerber, P. Loetscher, S. A. Jones, L. Piali, I. Clark-Lewis, M. Baggiolini, and B. Moser. 1996. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184:963.
21. Sgadari, C., A. L. Angiolillo, B. W. Cherney, S. E. Pike, J. M. Farber, L. G. Koniaris, P. Vanguri, P. R. Burd, N. Sheikh, G. Gupta, J. Teruya-Feldstein, and G. Tosato. 1996. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc. Natl. Acad. Sci. USA 93:13791.
22. Passaniti, A., R. M. Taylor, R. Pili, Y. Guo, P. V. Long, J. A. Haney, R. R. Pauly, D. S. Grant, and G. R. Martin. 1992. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67:519.
23. Drabkin, D. L., and J. H. Austin. 1932. Spectrophotometric constants for common hemoglobin derivatives in human, dog and rabbit blood. J. Biol. Chem. 98:719.
24. Khan, I. A., J. A. MacLean, F. S. Lee, L. Casciotti, E. DeHaan, J. D. Schwartzman, and A. D. Luster. 2000. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 12:483.
25. Lode, H. N., R. Xiang, N. M. Varki, C. S. Dolman, S. D. Gillies, and R. A. Reisfeld. 1997. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst. 89:1586.
26. Homann, D., A. Tishon, D. P. Berger, W. O. Weigle, M. G. von Herrath, and M. B. Oldstone. 1998. Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from muMT/muMT mice. J. Virol. 72:1208.
27. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Sherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827.
28. Brunda, M. J., L. Luistro, J. A. Hendrzak, M. Fountoulakis, G. Garotta, and M. K. Gately. 1995. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother. Emphasis Tumor Immunol. 17:71.
29. Manetti, R., P. Parronchi, M. G. Giudizi, M. P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199.
30. Brunda, M. J., L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf, and M. K. Gately. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J. Exp. Med. 178:1223.
31. Trinchieri, G. 1993. Interleukin-12 and its role in the generation of TH1 cells. Immunol. Today 14:335.
32. Brunda, M. J. 1994. Interleukin-12. J. Leukocyte Biol. 55:280.
33. Brunda, M. J., and M. K. Gately. 1994. Antitumor activity of interleukin-12. Clin. Immunol. Immunopathol. 71:253.
34. Trinchieri, G., and P. Scott. 1994. The role of interleukin 12 in the immune response, disease and therapy. Immunol. Today 15:460.
35. Brunda, M. J., L. Luistro, L. Rumennik, R. B. Wright, Dvorozniak, A. Aglione, J. M. Wigginton, R. H. Wiltrout, J. A. Hendrzak, and A. V. Palleroni. 1996. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother. Pharmacol. 38(Suppl.):S16.
36. Balicki, D., R. A. Reisfeld, U. Pertl, E. Beutler, and H. N. Lode. 2000. Histone H2A-mediated transient cytokine gene delivery induces efficient anti-tumor responses in murine neuroblastoma. Proc. Natl. Acad. Sci. USA 97:11500.
37. Sgadari, C., A. L. Angiolillo, and G. Tosato. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87:3877.
38. Tang, H. L., and J. G. Cyster. 1999. Chemokine up-regulation and activated T cell attraction by maturing dendritic cells. Science 284:819.
39. Biragyn, A., K. Tani, M. C. Grimm, S. Weeks, and L. W. Kwak. 1999. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17:253.
40. Cella, M., Jarrossay, D., Facchetti, F., Alebardi, O., Nakajima, H., Lanzavecchia, A., and Colonna. M. 1999. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5:919.
41. Cella, M., Facchetti, F., Lanzavecchia, A., and Colonna, M. 2000. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat. Immunol. 1:305.